The success of Sildenafil initially sparked a period of growth for pharma, however recent developments present a complicated outlook for investors. Lower-cost alternatives are eroding revenue, and ongoing legal battles https://umaryvfz148560.is-blog.com/48119885/the-blue-pill-and-big-pharma-a-precarious-bet